Pharma BD Deal Intelligence

Sanofi SA / Belharra Therapeutics, Inc.

2024 · Licensing/Option · $700M · Complete

Sanofi and Belharra Therapeutics entered a strategic drug-discovery collaboration in which Belharra applies its non-covalent chemoproteomics platform to screen and validate hits against undisclosed Sanofi-designated immunology targets. Belharra is eligible for up to $40M in upfront and near-term milestone payments and up to nearly $700M in aggregate research, development and commercial milestones plus tiered royalties on net sales; Sanofi leads all subsequent preclinical, clinical and commercialization activities.

This deal is too recent to grade. Critic Score and Outcome Score are assigned after the announcement-week coverage settles and, for Outcome, after the 5-year post-close assessment window opens — expected 2029 at the earliest for this deal, once/if it closes.

Key facts

Related deals

See the full interactive analysis, sources & comparables →

← Browse all deals  ·  How we score deals

More: 2024 deals  ·  Sanofi SA deals